NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $13.10 +0.81 (+6.59%) Closing price 04:00 PM EasternExtended Trading$13.10 +0.01 (+0.04%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About 4D Molecular Therapeutics Stock (NASDAQ:FDMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FDMT alerts:Sign Up Key Stats Today's Range$12.29▼$13.3950-Day Range$11.47▼$16.7652-Week Range$6.96▼$16.93Volume725,370 shsAverage Volume854,742 shsMarket Capitalization$723.64 millionP/E RatioN/ADividend YieldN/APrice Target$28.90Consensus RatingModerate Buy Company Overview 4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs. Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, an inhaled gene therapy intended to deliver functional CFTR genes to the lungs of people with cystic fibrosis. These products remain investigational and have not been approved for commercial use. Founded in 2013, 4D Molecular Therapeutics is headquartered in Emeryville, California, and conducts research and clinical development activities primarily in the United States. The company was co-founded by David Kirn, who has served as its chief executive officer, and has built its business around applying engineered AAV vectors to address diseases that may benefit from targeted gene delivery.AI Generated. May Contain Errors. Read More 4D Molecular Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreFDMT MarketRank™: 3.487244220035 of 5 stars4D Molecular Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 231st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside Potential4D Molecular Therapeutics has a consensus price target of $28.90, representing about 120.6% upside from its current price of $13.10.Amount of Analyst Coverage4D Molecular Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 4D Molecular Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to grow in the coming year, from ($4.14) to ($4.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -4.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 4D Molecular Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted22.09% of the float of 4D Molecular Therapeutics has been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 9.33.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently decreased by 6.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for 4D Molecular Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for FDMT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,780,316.00 in company stock.Percentage Held by Insiders7.90% of the stock of 4D Molecular Therapeutics is held by insiders.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 4D Molecular Therapeutics' insider trading history. Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FDMT Stock News HeadlinesComparing 4D Molecular Therapeutics (NASDAQ:FDMT) and Sangamo Therapeutics (NASDAQ:SGMO)October 19 at 4:58 AM | americanbankingnews.com4DMT Announces New Employment Inducement GrantsOctober 16, 2026 | globenewswire.comTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.October 20 at 1:00 AM | Porter & Company (Ad)4D Molecular Therapeutics Inc (FDMT)October 16, 2026 | au.investing.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Consensus Price Target of $28.90 According to AnalystsOctober 13, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Viking Therapeutics (VKTX)October 9, 2026 | theglobeandmail.com4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 58,333 Shares of StockOctober 8, 2026 | insidertrades.comInsider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells 1,635 Shares of StockSeptember 23, 2026 | insidertrades.comSee More Headlines FDMT Stock Analysis - Frequently Asked Questions How have FDMT shares performed this year? 4D Molecular Therapeutics' stock was trading at $7.50 at the start of the year. Since then, FDMT stock has increased by 74.7% and is now trading at $13.10. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by $0.02. The company had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 41.33% and a negative net margin of 194.74%. When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $189 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 8,400,000 shares at a price of $22.00-$23.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? 4D Molecular Therapeutics' top institutional investors include Toth Financial Advisory Corp. Insiders that own company stock include Global Investors Lp Viking, David Kirn, Ashoo Gupta, Scott Bizily and Robert Young Kim. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 4D Molecular Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D Molecular Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Viking Therapeutics (VKTX), Palantir Technologies (PLTR), Plug Power (PLUG), Tesla (TSLA) and Cabaletta Bio (CABA). Company Calendar Last Earnings8/13/2026Today10/20/2026Investor Day 202610/21/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 FDMT's financial health is in the Green zone, according to TradeSmith. FDMT has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FDMT CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees196Year Founded2013Price Target and Rating Average Price Target for 4D Molecular Therapeutics$28.90 High Price Target$37.00 Low Price Target$17.00 Potential Upside/Downside+120.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.11 million Net Margins-194.74% Pretax Margin-194.74% Return on Equity-41.33% Return on Assets-35.90% Debt Debt-to-Equity Ratio0.05 Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$85.21 million Price / Sales8.49 Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book1.48Miscellaneous Outstanding Shares55,240,000Free Float50,880,000Market Cap$723.64 million OptionableOptionable Beta2.75 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:FDMT) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
